{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.30","upperLimit":"14.06","value":"12.71"},{"groupId":"OG001","lowerLimit":"7.66","upperLimit":"9.72","value":"8.54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"381"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG000","title":"Panobinostat + Bortezomib"},{"description":"Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"45 months","title":"Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","type":"SECONDARY","unitOfMeasure":"months"}